ArticleProtein science : a publication of the Protein Society2026
Site-specific O-glycans influence lacritin structure and multimerization in tears.
Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Lacritin is an abundantly expressed glycoprotein in tear fluid and plays key roles in immune response, tear secretion, and bacterial killing. These biological functions are tightly regulated through several biochemical mechanisms including multimerization, proteolysis, and alternative splicing, especially within its C-terminal domain. Given its critical role at the ocular surface, lacritin is currently under investigation as a diagnostic biomarker and therapeutic candidate for dry eye disease (DED). However, despite over three decades since its initial discovery, the functional significance of the O-glycans that comprise more than 50% of its molecular weight remains largely unknown. To address this gap, we leveraged mass spectrometry (MS)-based glycoproteomics, AlphaFold 3.0, and molecular dynamics (MD) to explore the structural role of site-specific O-glycans on C-terminal lacritin. In doing so, we identified distinct glycosylation profiles between monomeric and multimeric lacritin, particularly at glycosites located near crosslinking residues (Lys101 and Lys104) that modulate multimer formation. Based on our glycoproteomics data, we performed MD simulations on monomer and multimer glycoforms and revealed that O-glycans may participate in intramolecular glycan-protein interactions that influence its structure and the spatial arrangement of Lys101 and Lys104. Differences in the solvent accessible surface area (SASA) and root mean squared fluctuation (RMSF) of these residues further suggested that proximal O-glycosylation could affect their ability to participate in crosslinking. To test these predictions, we performed in vitro crosslinking assays and demonstrated reduced TGM2-mediated multimerization of glycosylated versus unmodified lacritin. Finally, we show that recombinant glycoforms bearing O-glycan patterns similar to endogenous lacritin multimers are enriched after TGM2 crosslinking. Taken together, these findings underscore a central role for lacritin O-glycans in affecting structural topology and multimerization with implications for its downstream biological activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.